Business · 11/02/1997Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Patent Extension of MERREM I.V.
Summary
The Food and Drug Administration has officially confirmed the review period for the patent extension application of MERREM I.V., a human drug product, as required by law, following a submission to the Commissioner of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →